SARS-CoV-2 Antibody Diagnostic testing on the ZIVA platform
New Platform Technology for ELISA assays
A new novel Cavidi Platform Technology is used for detecting disease earlier, sometimes pre-symptomatically, and with minimally invasive blood testing. It has also been shown that sensitivity can lead to improved specificity and quantitation, helping to reduce false positives and false negatives in biomarker detection. These advances are being realized today in promising new COVID-19 serology tests under development. Achieving even greater sensitivity further advances the field of high-sensitivity biomarker detection by enabling biomarker subtypes to be measured and quantified, further stratifying disease cohorts and enabling precision health studies. This advance may also benefit point-of-care solutions and drug and vaccine research, diagnostics and disease prevention sciences.
Enzyme Enhanced ELISA – allows much lower detection limits
The greater sensitivity carries particular significance in the fight against COVID-19 by enabling greater detection of proteins central to infectious diseases, namely, viral antigens, and the antibodies and cytokines that are generated during host response. For example, improved sensitivity will further improve Cavidi’s ability to measure cytokine concentrations associated with cytokine release, a severe immune response to the virus.
Cavidi is working to add a SARS-CoV-2 antibody serology test to our newly developed fully automated ZIVA system analyzer, a multi-assay platform. ZIVA is an ultra-sensitive immuno-assay technology platform fully capable of adding new test assays, including SARS-CoV-2 antibody detection and monitoring.
ZIVA was designed to deliver cutting edge technology for mid-tier laboratories in Low and Middle Income Countries; very robust, easy to use, and fit for purpose. We have a system concept that allows us to add future immunoassay tests with simple software script and highly sensitive reagent kits optimized to run on ZIVA. We are currently developing a quantitative serological assay to detect IgM and IgG as well as neutralizing antibodies against SARS-CoV-2 to aid in detection of active infection as well as to identify previously infected individuals (see chart below). We are working with local Nordic partners who already have a rapid test for antigens and access to clinical samples from hospitals which will shorten development time.
Our value add would be to provide the ZIVA system with batch run, load and walk away simplicity, for up to 90 test results in a few hours.